登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由四川大学华西医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07463248,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Child Pugh score ≤ 7 points;
入选标准第 5 条
Received abdominal radiotherapy or administered radioactive substances within 28 days prior to PD-1 monoclonal antibody re-challenge;
排除标准第 3 条
The Eastern Oncology Consortium (ECOG) Behavioral status score was 0 or 1.
入选标准第 7 条
Subject must have at least 1 measurable target lesion examined by CT or MRI according to RECIST1.1 criteria;
入选标准第 6 条
Known history of primary immunodeficiency or HIV infection;
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;化验:血常规、肝肾功能;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07463248,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Clinically or pathologically confirmed unresectable primary hepatocellular carcinoma; Liver cancer patients with BCLC stage B or C; Not receiving systematic treatment before enrollment; Patients with acquired resistance who achieved disease control (DCR: CR, PR, or SD) following first-line targeted-immunotherapy but later experienced disease progression (PD); Child Pugh score ≤ 7 points; Subject must have at least 1 measurable target lesion examined by CT or MRI according to RECIST1.1 criteria; The Eastern Oncology Consortium (ECOG) Behavioral status score was 0 or 1.排除标准:Exclusion Criteria:
Failure to recover to NCI-CTC AE Grade ≤1 (excluding alopecia and fatigue) or to baseline level from toxicities and/or complications of prior interventions before PD-1 monoclonal antibody re-challenge; Subjects requiring systemic therapy with corticosteroids (>10 mg prednisone equivalent daily) or other immunosuppressive agents within 14 days prior to PD-1 monoclonal antibody re-challenge; Received abdominal radiotherapy or administered radioactive substances within 28 days prior to PD-1 monoclonal antibody re-challenge; History of gastrointestinal perforation and/or fistula within 6 months prior to PD-1 monoclonal antibody re-challenge; Active gastrointestinal bleeding within 1 week before the first fecal microbiota transplantation. Occurrence of infection within 28 days prior to PD-1 monoclonal antibody re-challenge; Active infection requiring systemic antimicrobial therapy before PD-1 monoclonal antibody re-challenge and intestinal microbiota transplantation, excluding local infections requiring only topical antibiotics (e.g., skin infections); Received live or attenuated vaccines within 30 days prior to PD-1 monoclonal antibody re-challenge, or planned vaccination during the study period; Known history of primary immunodeficiency or HIV infection; Active or previously documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, chronic diarrhea), except patients with chronic diarrhea who had no recurrence within 2 years before enrollment; Known history of active tuberculosis (TB); Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; Suffering from active, known or suspected autoimmune disease, or with a history of autoimmune disease; History of cardiovascular or cerebrovascular events or accidents within 6 months; Other conditions deemed by the investigator to be inappropriate for enrollment, including patients with hyperprogressive disease.
引自 ClinicalTrials.gov, NCT07463248, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07463248,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。